MNPR Stock Overview
A clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Monopar Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.71 |
| 52 Week High | US$38.50 |
| 52 Week Low | US$1.37 |
| Beta | 1.1 |
| 11 Month Change | 275.43% |
| 3 Month Change | 666.93% |
| 1 Year Change | 1,175.73% |
| 33 Year Change | -16.31% |
| 5 Year Change | n/a |
| Change since IPO | -85.12% |
Recent News & Updates
Recent updates
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully
Aug 13
Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?
Feb 27Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?
Mar 02We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully
Nov 16Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive
Oct 05We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate
Jul 30Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans
Mar 28We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely
Jul 15Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation
Mar 26Monopar nabs U.S. patent covering camsirubicin
Dec 22Monopar Therapeutics selects targeted immuno-therapeutic candidate for COVID-19
Dec 10Monopar launches validive mid-stage study in chemo-induced oral mucositis
Dec 08Monopar Therapeutics EPS beats by $0.02
Nov 12Shareholder Returns
| MNPR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.1% | -3.7% | 0.3% |
| 1Y | 1,175.7% | 15.2% | 31.1% |
Return vs Industry: MNPR exceeded the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: MNPR exceeded the US Market which returned 30.3% over the past year.
Price Volatility
| MNPR volatility | |
|---|---|
| MNPR Average Weekly Movement | 169.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MNPR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MNPR's weekly volatility has increased from 90% to 170% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 10 | Chandler Robinson | www.monopartx.com |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers.
Monopar Therapeutics Inc. Fundamentals Summary
| MNPR fundamental statistics | |
|---|---|
| Market cap | US$100.28m |
| Earnings (TTM) | -US$6.47m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-16.1x
P/E RatioIs MNPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MNPR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.47m |
| Earnings | -US$6.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.23 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MNPR perform over the long term?
See historical performance and comparison